|ROCHESTER, N.Y.--(BUSINESS WIRE)--May 10, 2005--Biophan Technologies, Inc. (OTCBB:BIPH - News), a developer of next-generation medical technology, will present an overview of its nanotechnology solutions for the multi-billion-dollar healthcare markets as a presenting company at the NSTI Nanotech Ventures Showcase & the NSTI Nanotechnology Conference and Trade Show, to be held May 8-12 at the Anaheim Marriott Hotel & Convention Center, in Anaheim, CA.|
NSTI Nanotech Ventures Showcase runs concurrently with NSTI Nanotech 2005 Conference and Trade Show, now celebrating its 8th year, the world’s largest nanotechnology conference of its kind. The five-day conference provides over 60 sessions on business and finance related to nanotechnology.
On May 11th, Mr. Weiner will join other nanotechnology industry leaders in a moderated discussion entitled “Nanotechnology Companies and the Public Equity Markets” to cover a range of subjects, including the potential impact and opportunities that nanotechnology companies may face when involved in the public equity markets. The moderated panel discussion will be featured at 4:00pm in Salon A-B.
This event will also unite early stage public companies with industrial users, technology providers and the media and analyst community. Biophan will present an overview presentation for the attending industry experts at approximately 5:45pm on Tues, May 10. This venue will be used to promote commercial maturation across the nanotechnology landscape globally, from technology to products.
The NSTI provides analysis and information services for government, business and industrial clients worldwide. The NSTI Ventures Showcase also profiles new companies and technologies and encourages business and scientific discussion among nanotech and financial industry leaders. The NSTI staff and vast network of science advisors provide confidential technology and product review services covering all domains of nano, bio, and micro technologies.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA’s Ames Center for Nanotechnology. Biophan’s goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan’s actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan’s ability to develop its technologies; the approval of Biophan’s patent applications; the successful implementation of Biophan’s research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan’s technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan’s technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with Biophan’s periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
Jennifer Gould, 212-843-8037